Climb Bio (CLYM) Competitors $1.34 +0.08 (+6.35%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. BNTC, TRDA, MBX, GLUE, RNAC, ATAI, ATYR, CMPX, CYRX, and ATXSShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Benitec Biopharma (BNTC), Entrada Therapeutics (TRDA), MBX Biosciences (MBX), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Atai Life Sciences (ATAI), Atyr PHARMA (ATYR), Compass Therapeutics (CMPX), Cryoport (CYRX), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Benitec Biopharma Entrada Therapeutics MBX Biosciences Monte Rosa Therapeutics Cartesian Therapeutics Atai Life Sciences Atyr PHARMA Compass Therapeutics Cryoport Astria Therapeutics Benitec Biopharma (NASDAQ:BNTC) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Which has preferable earnings & valuation, BNTC or CLYM? Benitec Biopharma has higher revenue and earnings than Climb Bio. Benitec Biopharma is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K3,983.74-$21.75M-$1.51-9.00Climb BioN/AN/A-$35.12M-$2.13-0.63 Which has more risk & volatility, BNTC or CLYM? Benitec Biopharma has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Do analysts recommend BNTC or CLYM? Benitec Biopharma currently has a consensus price target of $24.71, suggesting a potential upside of 81.86%. Climb Bio has a consensus price target of $10.00, suggesting a potential upside of 646.27%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media refer more to BNTC or CLYM? In the previous week, Benitec Biopharma had 2 more articles in the media than Climb Bio. MarketBeat recorded 3 mentions for Benitec Biopharma and 1 mentions for Climb Bio. Benitec Biopharma's average media sentiment score of 1.56 beat Climb Bio's score of 0.93 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Overall Sentiment Benitec Biopharma Very Positive Climb Bio Positive Do institutionals and insiders believe in BNTC or CLYM? 52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 3.2% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is BNTC or CLYM more profitable? Climb Bio's return on equity of -42.21% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -44.61% -41.25% Climb Bio N/A -42.21%-41.39% Does the MarketBeat Community believe in BNTC or CLYM? Benitec Biopharma received 195 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 65.67% of users gave Benitec Biopharma an outperform vote. CompanyUnderperformOutperformBenitec BiopharmaOutperform Votes19765.67% Underperform Votes10334.33% Climb BioOutperform Votes2100.00% Underperform VotesNo Votes SummaryBenitec Biopharma beats Climb Bio on 10 of the 17 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.42M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.637.4422.4818.48Price / SalesN/A242.70395.93103.60Price / CashN/A65.8538.1834.62Price / Book0.346.516.774.25Net Income-$35.12M$143.21M$3.22B$248.23M7 Day Performance3.08%1.98%1.47%0.89%1 Month Performance11.67%6.89%3.99%3.53%1 Year PerformanceN/A-2.52%16.15%5.08% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.9667 of 5 stars$1.34+6.3%$10.00+646.3%N/A$90.42MN/A-0.639Gap DownBNTCBenitec Biopharma2.6972 of 5 stars$14.21+4.0%$24.71+74.0%+60.8%$333.12M$80,000.00-9.4120Positive NewsTRDAEntrada Therapeutics2.8762 of 5 stars$8.85+1.6%$25.67+190.0%-23.0%$332.68M$210.78M5.57110Upcoming EarningsNews CoveragePositive NewsMBXMBX Biosciences2.5913 of 5 stars$9.62+7.0%$37.50+290.0%N/A$321.37MN/A0.0036GLUEMonte Rosa Therapeutics1.9756 of 5 stars$5.20-2.4%$15.50+198.1%-7.7%$316.16M$75.62M-2.8190Upcoming EarningsShort Interest ↑News CoverageRNACCartesian Therapeutics1.9551 of 5 stars$12.05+3.6%$42.67+254.1%-45.6%$309.82M$38.91M-0.2364Upcoming EarningsGap DownATAIAtai Life Sciences2.6737 of 5 stars$1.52-0.3%$10.50+593.1%-24.2%$302.67M$308,000.00-1.8780Positive NewsATYRAtyr PHARMA2.3959 of 5 stars$3.40-3.6%$18.60+447.9%N/A$300.79M$235,000.00-3.6053Short Interest ↑News CoverageCMPXCompass Therapeutics3.3928 of 5 stars$2.15+3.6%$13.38+523.5%+29.2%$293.85M$850,000.00-5.7420Analyst ForecastShort Interest ↑Analyst RevisionCYRXCryoport2.3918 of 5 stars$5.88+5.2%$11.67+98.4%-65.5%$293.47M$228.39M-1.741,020Gap DownATXSAstria Therapeutics2.5347 of 5 stars$5.18-0.3%$26.60+413.1%-43.8%$292.33MN/A-2.4830Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Benitec Biopharma Competitors Entrada Therapeutics Competitors MBX Biosciences Competitors Monte Rosa Therapeutics Competitors Cartesian Therapeutics Competitors Atai Life Sciences Competitors Atyr PHARMA Competitors Compass Therapeutics Competitors Cryoport Competitors Astria Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLYM Stock Free CLYM Stock Alerts